Novavax, Inc. (NASDAQ:NVAX) Q1 2022 Results Earnings Conference Call May 9, 2022 4:30 PM ET

Company Participants

Silvia Taylor - SVP, Global Corporate Affairs & IR

Stan Erck - President, CEO

John Trizzino - EVP & Chief Business & Commercial Officer

Filip Dubovsky - EVP & Chief Medical Officer

James Kelly - EVP, CFO & Treasurer

Greg Glenn - President, Research and Development

Conference Call Participants

Roger Song - Jefferies

Georgi Yordanov - Cowen and Company

Eric Joseph - JPMorgan

Mayank Mamtani - B. Riley Securities

Vernon Bernardino - H.C. Wainright

Operator

Good afternoon, and welcome to the Novavax First Quarter 2022 Financial Results and Operational Highlights Conference Call. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Silvia Taylor, Senior Vice President of Global Corporate Affairs and Investor Relations. Please go ahead.

Silvia Taylor

Good afternoon, and thank you all for joining us today to discuss our first quarter 2022 operational highlights and financial results. A press release announcing our results is currently available on our website at novavax.com, and an audio archive of this conference call will be available on our website later today.

Before we begin with prepared remarks, I need to remind you that we will be making forward-looking statements during this teleconference, which are based on our current expectations and beliefs. For example, statements related to 2022 financial guidance, future financial or business performance, conditions or strategy including expectations regarding revenues, product demand, operating expenses, gross margins, cash usage, clinical development of our vaccine candidates, timing of future regulatory filings, authorizations and actions and other anticipated milestones are forward-looking statements.

Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties and change over time, and actual results could differ materially from what is described in such statements.

Please turn to Slide 3. During this call, we will be referring to a non-GAAP financial measure, which is not prepared in accordance with U.S. generally accepted accounting principles. The most directly comparable financial measure calculated in accordance with GAAP and a reconciliation of GAAP to the non-GAAP measure is contained in the presentation and is available on our website at ir.noavax.com.

Please turn to Slide 4. Joining me today is Stan Erck, President and CEO, who will provide an overview of recent achievements and our upcoming strategic priorities. Additionally, John Trizzino, Chief Commercial Officer and Chief Business Officer, will provide an update on the status of our global COVID-19 vaccine rollout and our current regulatory progress. Dr. Filip Dubovsky, Chief Medical Officer, will discuss our clinical and regulatory strategy across our pipeline, and Jim Kelly, Chief Financial Officer and Treasurer, will provide an overview of our financial results. Dr. Greg Glenn, President of Research and Development, will also be available for the Q&A section at the end of today's call.